Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 5Esophageal Squamous Cell Carcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Stomach Neoplasms 2Neoplasms 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Rectal Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endometrial Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Levoleucovorin × 1 year × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06780111 2026-03-31

MK-3475-06E

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
298 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡